

Curriculum Vitae

Name	Hee Seung Lee	
Country	South Korea	
Organization	Yonsei University College of Medicine	
Current Position	Associate professor	

Educational Background

- 2001.3 ~ 2007.2 Yonsei University College of Medicine, Korea

Professional Experiences

- 2007.3~2008.2: Internship, Severance Hospital, Yonsei University College of Medicine
- 2011.3~2015.2: Residency Severance Hospital, Yonsei University College of Medicine
- 2015.3~2016.2: Fellowship, Severance Hospital, Yonsei University College of Medicine
- 2016.3~2018.2: Clinical research assistant professor, Yonsei University College of Medicine
- 2018.3~2023.2: Clinical assistant professor, Yonsei University College of Medicine
- 2019.6~2019.7: Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge
- 2022.9~2022.11: Indiana University, Gastroenterology department (visiting scholar)
- 2023.9~2024.8: KAIST, Graduate School of Medical Science and Engineering (visiting scholar)
- 2023.3~Present: Associate professor, Yonsei University College of Medicine
- 2024.7~Present: Adjunct Scholar, Team leader, Center for Genome Engineering, IBS

Research Field or Main Scientific Publications

Research field
Metastasis, Plasticity, Tumor microenvironment, Chemoresistance, Pancreatic cancer, Bile duct cancer, Cancer organoids

Selected Publications

1. Yoo Keung Tae, Sang-Min Kim, et al. Fluid-derived pancreatic cancer organoids reveal CEMIP, CALB2, and LY6D as drivers of chemotherapy resistance. *Cancer cell international*. 2026. Accepted.
 2. Lee HS, Koo B-K. Patient-derived organoids in pancreatic cancer: Advances and applications in precision oncology. *Cancer Biome and Targeted Therapy*. 2026 Aug 12;57–83.
 3. Hye Yeon Chon, Hyungjin Rhee, Jeehoon Kim, et al. Impact of metabolic dysfunction-associated steatotic liver disease on liver metastasis and survival in pancreatic cancer, *World Journal of Gastroenterology*. 2026
 4. Ko YG, Lee SY, Lee WK, et al. Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine learning model. *BMC Cancer*. 2025 Nov 27;26(1):61.
 5. Ko YG, Jo JH, Song SY, Lee HS*. The crucial role of CEMIP in cancer metastasis: Mechanistic insights and clinical implications. *FASEB J* 2025;39:e70284.
 6. Keum J, Lee HS*, Park CS, et al. Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study. *Ther Adv Med Oncol* 2024;16.
 7. Lee HS*, Han DH, Cho K, et al. Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping. *Nat Commun*. 2023 Jan 16;14(1):237.
 8. Yoo HB, Moon JW, Kim HR, et al. A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer. *Gastroenterology*. 2023 Jul;165(1):133-148.e17.
 9. Lee HS*, Chae W, Sung MJ, et al. Difference of Risk of Pancreatic Cancer in New-Onset Diabetes and Long-standing Diabetes: A Population-based Cohort Study. *J Clin Endocrinol Metab*. 2023 May 17;108(6):1338-1347.
 10. Lee HS*, Jung EH, Shin H, et al. Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients with pancreatic cancer: a prospective study. *Front Oncol* 2023;13:1206565.
 11. Park SJ, Yoo HC, Ahn E, et al. Enhanced glutaminolysis drives hypoxia-induced chemoresistance in pancreatic cancer, *Cancer research*, 2023
 12. Lee HS*, Kim E, Lee J, et al. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. *EBioMedicine*. 2021 Mar;65:103218.
-